Coya Therapeutics: Early COYA 302 Validation, Regulatory De-Risking, and Upcoming Catalysts Support Buy Rating

Ram Selvaraju, an analyst from H.C. Wainwright, reiterated the Buy rating on Coya Therapeutics, Inc.. The associated price target remains the same with $18.00.

Ram Selvaraju has given his Buy rating due to a combination of factors that underscore both the scientific and commercial potential of Coya Therapeutics. He highlights encouraging early clinical findings for COYA 302 in frontotemporal dementia (FTD), where the therapy demonstrated strong engagement of its intended immune targets, with meaningful and sustained increases in regulatory T-cell activity and counts. Notably, patients in this small, open-label study maintained stable cognitive performance over the 22-week treatment period, which is notable given the progressive nature of FTD and the absence of approved disease-modifying therapies. While he acknowledges the limitations of the study’s size and duration, he views these data as an important validation of the company’s approach and a rationale for more rigorous, controlled trials.
Selvaraju also emphasizes the de-risking impact of the FDA’s acceptance of Coya’s IND for COYA 302 in FTD, which clears the way for a company-sponsored U.S. clinical program and formalizes the development pathway. He points to a series of upcoming catalysts across the pipeline—including biomarker and proteomic readouts in ALS and Alzheimer’s disease, as well as preclinical data for COYA 303—that could provide multiple opportunities for value creation in the near to medium term. In his view, the combination of positive proof-of-concept data, regulatory progress, and a rich catalyst calendar supports the continuation of his Buy rating and the 12-month price target he has set for the shares.

Selvaraju covers the Healthcare sector, focusing on stocks such as Vanda, Genmab, and Anavex Life Sciences. According to TipRanks, Selvaraju has an average return of 27.7% and a 57.40% success rate on recommended stocks.